However, a meta-analysis demonstrated that increased pCR rates do not correlate simply with improved long-term outcomes (26), likely due to tumor heterogeneity, differences in the effects of adjuvant treatments (e.g., endocrine therapy and HER-2 targeted therapy), and the presence of residual tumor cells at the molecular level. Here, ERBB2 is linked to neoplasm.